Sankey It
Loading...
Johnson & Johnson FY2024 income statement | Sankey It
Sankey It · JNJ
Johnson & Johnson FY2024 income statement
USD · fiscal year ended 2024-12-29
FY2025
FY2024
FY2023
FY2022
FY2021
Quarterly
Annual
comfortable
compact
Hide amounts
Export
Fullscreen
Johnson & Johnson FY2024 income statement
Flow diagram with 10 nodes and 9 flows for Johnson & Johnson FY2024 income statement. Values: Innovative Medicine US$57B, MedTech US$31.9B, Revenue US$88.8B, Cost of Revenue US$27.5B, Gross Profit US$61.4B, Operating Expenses US$39.2B, Operating Income US$22.1B, Other Expense US$5.5B, Tax US$2.6B, Net Income US$14.1B.
Innovative Medicine
US$57B
+4% Y/Y
64% of revenue
MedTech
US$31.9B
+5% Y/Y
36% of revenue
Revenue
US$88.8B
+4% Y/Y
Cost of Revenue
(US$27.5B)
+3% Y/Y
31% of revenue
Gross Profit
US$61.4B
+5% Y/Y
69% margin
Operating Expenses
(US$39.2B)
+11% Y/Y
44% of revenue
Operating Income
US$22.1B
-5% Y/Y
25% margin
Other Expense
(US$5.5B)
-35% Y/Y
6% of revenue
Tax
(US$2.6B)
+51% Y/Y
3% of revenue
Net Income
US$14.1B
-60% Y/Y
16% margin
Net / profit
Inputs
Tax / cost
Copy link
Share on X
Open full screen